Development of Common Immuno-Oncology Tools for Studying Microenvironmental Interactions Across Tumor Types

The collaborative team will choose a standard set of Tumor Immune MicroEnvironment (TIME) markers that would be appropriate for use across tumor types and validate the marker panels and detection and quantitation methods across MCL sites. Using a high quality and commercially sourced reagents, and choosing a robust platform and methodology, a consensus approach for analysis of the will be developed by the MCL Pathology Working Group and CDMG, s. The approach will yield a well validated multiplex assay(s) that could ultimately be adopted for routine clinical use, in which the immune cell tumor infiltrates (ImmunoProfile) will be prognostic, though distributions and impacts may differ between tumor types, and will, in serial samples, aid in monitoring individual patient responses to immunotherapy.